# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-015757
Filing Date
2023-04-28
Accepted
2023-04-28 16:02:24
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | eypt_defa14a_04-28-2023.htm | DEFA14A | 25485
2 | GRAPHIC | img203172737_0.jpg | GRAPHIC | 2063805
3 | GRAPHIC | img203172737_1.jpg | GRAPHIC | 467804
| Complete submission text file | 0000950170-23-015757.txt |  | 3509593

Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51122 | Film No.: 23865752
SIC: 3826 Laboratory Analytical Instruments